Vladimir Filimonov

Vladimir Filimonov


Research Focus & Metrics

Academic Career Length

52Years (1975-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1994 in Biochemistry
Verified
Journal Article
Closed access
AVAna Rosa Viguera
Ana Rosa Viguera
Jose C MartinezJose C Martinez
Jose C Martinez
VFVladimir Filimonov
Vladimir Filimonov
PMP. L. Mateo
P. L. Mateo
LSL. Serrano
L. Serrano

1 January 1975 in The Journal of Chemical Thermodynamics
Verified
Journal Article
Closed access
PPP.L. Privalov
P.L. Privalov
VPV.V. Plotnikov
V.V. Plotnikov
VFVladimir Filimonov
Vladimir Filimonov

1 January 2000 in Protein Science
Verified
Journal Article
Open access
PDF file
VVVirtudes Villegas
Virtudes Villegas
JZJesús Zurdo
Jesús Zurdo
VFVladimir Filimonov
Vladimir Filimonov
FAFrancesc X. Avilés
Francesc X. Avilés
CDChristopher M. Dobson
Christopher M. Dobson
LSLuis Serrano
Luis Serrano
The activation domain of human procarboxypeptidase A2 (ADA2h) aggregates following thermal or chemical denaturation at acidic pH. The aggregated material contains well‐defined ordered structures with all the characteristics of the fibrils associated with amyloidotic diseases. Variants of ADA2h containing a series of mutations designed to increase the local stability of each of the two helical regions of the protein have been found to have a substantially reduced propensity to form fibrils. This arises from a reduced tendency of the denatured species to aggregate rather than from a change in the overall stability of the native state. The reduction in aggregation propensity may result from an increase in the stability of local relative to longer range interactions within the polypeptide chain. These findings show that the intrinsic ability of a protein to form amyloid can be altered substantially by protein engineering methods without perturbing significantly its overall stability or activity. This suggests new strategies for combating diseases associated with the formation of aggregated proteins and for the design of novel protein or peptide therapeutics.

1 July 1978 in Journal of Molecular Biology
Verified
Journal Article
Closed access
PPP.L. Privalov
P.L. Privalov
VFVladimir Filimonov
Vladimir Filimonov

1 October 1981 in European Journal of Biochemistry
Verified
Journal Article
Closed access
PDF file
VKVictor E. Koteliansky
Victor E. Koteliansky
MGMarina A. Glukhova
Marina A. Glukhova
MBMarina V. Benjamin
Marina V. Benjamin
VSVladimir N. Smirnov
Vladimir N. Smirnov
VFVladimir Filimonov
Vladimir Filimonov
SVSergei Yu. Venyaminov
Sergei Yu. Venyaminov

1 July 1978 in Journal of Molecular Biology
Verified
Journal Article
Closed access
VFVladimir Filimonov
Vladimir Filimonov
PPP.L. Privalov
P.L. Privalov